PIN25 PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN GERMANY
Staginnus U 1 , Russell S 2 1 Premor Associates, New York, NY, USA; 2 Premor Associates, Madrid, Spain OBJECTIVE: Increasing antibiotic resistant staphylococcus aureus strains in hospital-and chronic disease patients causing a high burden of illness and consume enormous health care resources in Germany. A new vaccine (StapVax) preventing S.aureus infections is in clinical development and currently seeking market authorization in the EU. The objective of this analysis is to project the potential economic value of vaccinating hemodialysis patients with StapVax against mecillin resistant staphylococcus aureus infections. METHODS: A literaturebased decision analysis model was developed to assess the annual number of potential infections and death avoided as well as to calculate cost-effectiveness, break-even price and budget impact of the candidate vaccine. Baseline efficacy rate was assumed to be 57% with a 90% coverage rate. The model compared projected cost per infection avoided and cost per life-year gained for patients receiving the vaccine versus unvaccinated patients undergoing hemodialysis. RESULTS: Vaccinating the about 60,000 hemodialysis patients in Germany could prevent 650 S.aureus infections and 105 associated deaths per year. Assuming annual per patient vaccination cost of €500 (vaccine plus administration) the cost per infection avoided was estimated at €27,000, with a cost per life-year gained of €17,000, respectively. The net-budget impact in this scenario results in about €18 million. Vaccination cost of €170 would make the vaccine a budget neutral preventive strategy. Monte Carlo simulations on vaccine efficacy, mortality rate after S.aureus infection, treatment and vaccination cost resulted in cost per life-year gained ranging from €3000 to €22,000 in 95% of the runs, and from €7000 to €14,000 in 50% of trial runs. The model is most sensitive to vaccine program cost and predicted preventive efficacy. CON-CLUSION: Vaccinating hemodialysis patients with StaphVax is a highly cost-effective measure to prevent serious morbidity and mortality in this patient population at substantial risk of bacterial contamination.
PIN26 COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORY TRACT INFECTIONS WITH NON-SPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT
Advanced Research Srl, Torino, Italy; 2 University of Turin, Torino, Italy OBJECTIVES: To estimate the pharmacoeconomic impact of preventing recurrent upper respiratory tract infections (URTIs) with OM-85, a non-specific immunostimulating agent, in at-risk children. METHODS: Implementation of a decisional model. The evaluation of effectiveness (number of prevented URTIs/therapeutic cycle) was based on weighted average of the results of four randomized, double-blind, placebo-controlled trials identified by literature reviewing. The clinical events considered in the model were natural resolution of the infection, onset of complications (acute otitis media, sinusitis, others) and their evolution. Baseline event probabilities were derived by reviewing published data in the literature. URTI-related direct and indirect costs supported by patients, by Italian health system and by community were structured according with the principal guidelines and implemented with current Italian prices and tariffs. The cost-effectiveness of OM-85 was calculated for five scenarios, differing in the number of therapeutic cycles, grade of patient co-payment and other secondary assumptions. Sensibility analyses were performed to evaluate the model robustness. RESULTS: Immunostimulation with one cycle of OM-85 prevented on average 1.60 URTI/patient in 6 months (RR = 0.515). In the basic scenario, this preventive action induced savings for €107.42/patient in the perspective of the patient's family, for €48.52/patient in the perspective of Italian health system and for 231.26 in the community perspective. Sensibility analyses confirmed the robustness of basic scenario results. Threshold analyses showed that OM-85 prophylaxis is economically convenient as long as more than 7% of infections are prevented or global cost of one episode of URTI is greater than €10.00. CONCLU-SIONS: Non-specific immunotherapy with OM-85 induces a reduction in the incidence of URTIs in at-risk children with a concurrent saving for patients and health system. 
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